These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 24802906)

  • 1. Paenibacterin, a novel broad-spectrum lipopeptide antibiotic, neutralises endotoxins and promotes survival in a murine model of Pseudomonas aeruginosa-induced sepsis.
    Huang E; Yousef AE
    Int J Antimicrob Agents; 2014 Jul; 44(1):74-7. PubMed ID: 24802906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosynthesis of the new broad-spectrum lipopeptide antibiotic paenibacterin in Paenibacillus thiaminolyticus OSY-SE.
    Huang E; Guo Y; Yousef AE
    Res Microbiol; 2014 Apr; 165(3):243-51. PubMed ID: 24607714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The lipopeptide antibiotic paenibacterin binds to the bacterial outer membrane and exerts bactericidal activity through cytoplasmic membrane damage.
    Huang E; Yousef AE
    Appl Environ Microbiol; 2014 May; 80(9):2700-4. PubMed ID: 24561581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibacterial Properties of Tebipenem Pivoxil Tablet, a New Oral Carbapenem Preparation against a Variety of Pathogenic Bacteria in Vitro and in Vivo.
    Yao Q; Wang J; Cui T; Yang Z; Su M; Zhao P; Yan H; Zhan Y; Yang H
    Molecules; 2016 Jan; 21(1):62. PubMed ID: 26751436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Draft genome sequence of Paenibacillus sp. strain OSY-SE, a bacterium producing the novel broad-spectrum lipopeptide antibiotic paenibacterin.
    Huang E; Guo Y; Yousef AE
    J Bacteriol; 2012 Nov; 194(22):6306. PubMed ID: 23105053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repurposing Non-Antimicrobial Drugs and Clinical Molecules to Treat Bacterial Infections.
    Younis W; Thangamani S; Seleem MN
    Curr Pharm Des; 2015; 21(28):4106-11. PubMed ID: 25961308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation of a Paenibacillus sp. strain and structural elucidation of its broad-spectrum lipopeptide antibiotic.
    Guo Y; Huang E; Yuan C; Zhang L; Yousef AE
    Appl Environ Microbiol; 2012 May; 78(9):3156-65. PubMed ID: 22367082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Battacin (Octapeptin B5), a new cyclic lipopeptide antibiotic from Paenibacillus tianmuensis active against multidrug-resistant Gram-negative bacteria.
    Qian CD; Wu XC; Teng Y; Zhao WP; Li O; Fang SG; Huang ZH; Gao HC
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1458-65. PubMed ID: 22183171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of para-guanidinoethylcalix[4]arene against susceptible and antibiotic-resistant Gram-negative and Gram-positive bacteria.
    Grare M; Mourer M; Fontanay S; Regnouf-de-Vains JB; Finance C; Duval RE
    J Antimicrob Chemother; 2007 Sep; 60(3):575-81. PubMed ID: 17626025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
    Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
    Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
    Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
    J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.
    Kanj SS; Whitelaw A; Dowzicky MJ
    Int J Antimicrob Agents; 2014 Feb; 43(2):170-8. PubMed ID: 24315313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Pexiganan Combination with Tigecycline in a Mouse Model of Pseudomonas aeruginosa Sepsis.
    Cirioni O; Simonetti O; Morroni G; Brescini L; Kamysz W; Kamysz E; Orlando F; Pierpaoli E; Caffarini M; Orciani M; Agostinelli C; Offidani A; Provinciali M; Giacometti A
    Curr Top Med Chem; 2018; 18(24):2127-2132. PubMed ID: 30569865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
    Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
    Jones ME
    Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using the number needed to treat to assess appropriate antimicrobial therapy as a determinant of outcome in severe sepsis and septic shock.
    Vazquez-Guillamet C; Scolari M; Zilberberg MD; Shorr AF; Micek ST; Kollef M
    Crit Care Med; 2014 Nov; 42(11):2342-9. PubMed ID: 25072764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
    Dowzicky MJ; Park CH
    Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum parenteral carbapenem.
    Ueda Y; Kanazawa K; Eguchi K; Takemoto K; Eriguchi Y; Sunagawa M
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4185-96. PubMed ID: 16189097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007.
    Garrison MW; Mutters R; Dowzicky MJ
    Diagn Microbiol Infect Dis; 2009 Nov; 65(3):288-99. PubMed ID: 19733459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.